AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23540865 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted biopsies using MRI/TRUS fusion
Number of subjects: 30
Study 23540865 — intervention group
Group type: COMPARATOR
Intervention: Randomized biopsies
Number of subjects: 30
Study 21712261 — intervention group
Group type: EXPERIMENTAL
Intervention: RVA+LV pacing mode
Number of subjects: 33
Study 21712261 — intervention group
Group type: EXPERIMENTAL
Intervention: RVOT+LV pacing mode
Number of subjects: 33
Study 21712261 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT (both RVA+LV and RVOT+LV)
Number of subjects: 33
Study 19196911 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training combined with plyometric jumps (9 weeks)
Number of subjects: 66
Study 16766440 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion for blindness with increased brightness of the light during suggestion in Study 1
Number of subjects: 43
Study 16766440 — intervention group
Group type: COMPARATOR
Intervention: Nonexperimental procedure in Study 2
Number of subjects: 43
Study 15385695 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR 12.5 mg
Number of subjects: 327
Study 15385695 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR 25 mg
Number of subjects: 327
Study 15385695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 11680282 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Reinforcement (CRF)
Number of subjects: 0
Study 11680282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Ratio (FR)
Number of subjects: 0
Study 11680282 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Ratio (VR)
Number of subjects: 0
Study 11680282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Interval (FI)
Number of subjects: 0
Study 11680282 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Interval (VI)
Number of subjects: 0
Study 9127855 — intervention group
Group type: EXPERIMENTAL
Intervention: Aircast brace
Number of subjects: 41
Study 9127855 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape bandage
Number of subjects: 41
Study 9127855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligafix brace
Number of subjects: 41
Study 9127855 — intervention group
Group type: EXPERIMENTAL
Intervention: Malleoloc brace
Number of subjects: 41
Study 9127855 — intervention group
Group type: COMPARATOR
Intervention: No stabilizing device
Number of subjects: 41
Study 9127855 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg jumping test
Number of subjects: 41
Study 7946224 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardianship networks
Number of subjects: 664
Study 7946224 — intervention group
Group type: COMPARATOR
Intervention: No guardianship networks
Number of subjects: 664
Study 3123132 — intervention group
Group type: EXPERIMENTAL
Intervention: Lng‐IUD
Number of subjects: 2758
Study 3123132 — intervention group
Group type: COMPARATOR
Intervention: Nova T
Number of subjects: 2758
Study 31169094 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training program
Number of subjects: 30
Study 31169094 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 31169094 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal perceived self-efficacy and locus of control
Number of subjects: 30
Study 29252040 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Glycemic Index (MGI) diet
Number of subjects: 17
Study 29252040 — intervention group
Group type: COMPARATOR
Intervention: Low Glycemic Index (LGI) diet
Number of subjects: 17
Study 27491361 — intervention group
Group type: COMPARATOR
Intervention: Day-time compression garment alone
Number of subjects: 120
Study 27491361 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-time compression garment + night-time compression bandaging
Number of subjects: 120
Study 27491361 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-time compression garment + use of a night-time compression system garment
Number of subjects: 120
Study 25600472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (SSG)
Number of subjects: 444
Study 25600472 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hypertonic saline (HS)
Number of subjects: 444
Study 25600472 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% hypertonic saline (HS)
Number of subjects: 444
Study 22995323 — intervention group
Group type: EXPERIMENTAL
Intervention: SB‐656933 50mg once daily for 28 days
Number of subjects: 146
Study 22995323 — intervention group
Group type: EXPERIMENTAL
Intervention: SB‐656933 20mg once daily for 28 days
Number of subjects: 146
Study 22995323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 21908943 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayonnaise (MS)
Number of subjects: 9
Study 21908943 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study 21908943 — intervention group
Group type: COMPARATOR
Intervention: Carrot Juice (JU)
Number of subjects: 9
Study 21908943 — intervention group
Group type: COMPARATOR
Intervention: Carrot with Oil (OIL)
Number of subjects: 9
Study 19106506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy with S‐1 and cisplatin (IP group)
Number of subjects: 8
Study 19106506 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy with S‐1 and cisplatin (IV group)
Number of subjects: 8
Study 16624457 — intervention group
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN "adults" (first vaccination)
Number of subjects: 3966
Study 16624457 — intervention group
Group type: COMPARATOR
Intervention: Encepur (comparator vaccine, first vaccination)
Number of subjects: 3966
Study 16624457 — intervention group
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN "adults" (second vaccination)
Number of subjects: 3966
Study 16624457 — intervention group
Group type: COMPARATOR
Intervention: Encepur (comparator vaccine, second vaccination)
Number of subjects: 3966
Study 16624457 — intervention group
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN "adults" (third vaccination)
Number of subjects: 3966
Study 16624457 — intervention group
Group type: COMPARATOR
Intervention: Encepur (comparator vaccine, third vaccination)
Number of subjects: 3966
Study 16624457 — intervention group
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN "adults" (immunogenicity)
Number of subjects: 3966
Study 16624457 — intervention group
Group type: COMPARATOR
Intervention: Encepur (immunogenicity)
Number of subjects: 3966
Study 14648410 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue-directed biopsy (MBDB)
Number of subjects: 57
Study 14648410 — intervention group
Group type: COMPARATOR
Intervention: Random biopsy
Number of subjects: 57
Study 11498896 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 63
Study 11498896 — intervention group
Group type: COMPARATOR
Intervention: Piracetam (Control)
Number of subjects: 63
Study 9798957 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Hz magnetic field (0.6 mT)
Number of subjects: 16
Study 9798957 — intervention group
Group type: COMPARATOR
Intervention: Static magnetic field (0.6 mT)
Number of subjects: 16
Study 8068472 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg/day
Number of subjects: 28
Study 8068472 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 100 mg/day
Number of subjects: 28
Study 8068472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3181276 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet activating factor (PAF) 26 micrograms
Number of subjects: 12
Study 3181276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29452685 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic stimulation plus medical therapy
Number of subjects: 251
Study 29452685 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 251
Study 27943563 — intervention group
Group type: EXPERIMENTAL
Intervention: DCV-TRIO (daclatasvir 30 mg, asunaprevir 200 mg, beclabuvir 75 mg) twice-daily + sofosbuvir 400 mg once-daily for 4 weeks
Number of subjects: 28
Study 27943563 — intervention group
Group type: EXPERIMENTAL
Intervention: DCV-TRIO (daclatasvir 30 mg, asunaprevir 200 mg, beclabuvir 75 mg) twice-daily + sofosbuvir 400 mg once-daily for 6 weeks
Number of subjects: 28
Study 27943563 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with DCV-TRIO + RBV for 12 weeks
Number of subjects: 28
Study 27943563 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline HCV-RNA <2 million IU/mL
Number of subjects: 28
Study 27943563 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline HCV-RNA ≥2 million IU/mL
Number of subjects: 28
Study 25302932 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D MUSIC technique
Number of subjects: 8
Study 25302932 — intervention group
Group type: COMPARATOR
Intervention: Ferumoxytol-based first-pass CE-MRA
Number of subjects: 8
Study 24168554 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral fracture (classified by appearance, number, severity, and location)
Number of subjects: 2132
Study 24168554 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted FVC, FEV1, and FEV1/FVC values
Number of subjects: 2132
Study 24168554 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive and restrictive ventilatory impairment
Number of subjects: 2132
Study 21174610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored and dose-dense EC followed by docetaxel (arm A)
Number of subjects: 124
Study 21174610 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose EC followed by docetaxel (arm B)
Number of subjects: 124
Study 21174610 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel, doxorubicin and cyclophosphamide (arm C)
Number of subjects: 124
Study 18339132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g/d
Number of subjects: 100
Study 18339132 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus (SRL) loading dose of 15 mg, 5 mg/d till day 7 and 2 mg/d thereafter
Number of subjects: 100
Study 16542443 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused follow-up (n = 53)
Number of subjects: 703
Study 16542443 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n = 50)
Number of subjects: 703
Study 12685885 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir 10 mg via Diskhaler twice daily for 5 days
Number of subjects: 588
Study 12685885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 11105734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg daily, titrated to a maximum of 200 mg daily)
Number of subjects: 310
Study 11105734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 310
Study 11105734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 9365042 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum anti‐p53 antibody positivity
Number of subjects: 86
Study 9365042 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin
Number of subjects: 86
Study 9365042 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 antibody
Number of subjects: 86
Study 9365042 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐fetoprotein (AFP)
Number of subjects: 86
Study 9365042 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green retention time at 15 min (ICG)
Number of subjects: 86
Study 9365042 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin and p53 antibody
Number of subjects: 86
Study 1556197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy (SI)
Number of subjects: 103
Study 1556197 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual-Motor Training (PM)
Number of subjects: 103
Study 1556197 — intervention group
Group type: COMPARATOR
Intervention: No Treatment (NT)
Number of subjects: 103
Study 30955980 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 booster dose of 45 mcg of IIV1 A/H7N9 hemagglutinin
Number of subjects: 27
Study 30955980 — intervention group
Group type: COMPARATOR
Intervention: AS03-adjuvanted IIV1 A/H7N9
Number of subjects: 27
Study 29719927 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 142
Study 29719927 — intervention group
Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Number of subjects: 142
Study 27183909 — intervention group
Group type: EXPERIMENTAL
Intervention: R-EPOCH
Number of subjects: 176
Study 27183909 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 176
Study 24434889 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper thoracic manipulation
Number of subjects: 32
Study 24434889 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure in the thoracic region
Number of subjects: 32
Study 22974273 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD-I (structured interview assessing the patient's perspective)
Number of subjects: 0
Study 22974273 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD-Q (questionnaire assessing the clinician's perspective)
Number of subjects: 0
Study 22974273 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD (both RAD-I and RAD-Q)
Number of subjects: 0
Study 19892414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care intervention (professional oral care from a dentist three times a week for 1 year)
Number of subjects: 53
Study 19892414 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral care intervention)
Number of subjects: 53
Study 17109723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 100
Study 17109723 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 100
Study 16198248 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration <120 ms
Number of subjects: 248
Study 16198248 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration 120‐159 ms
Number of subjects: 248
Study 16198248 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration > or = 160 ms
Number of subjects: 248
Study 16198248 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration
Number of subjects: 248
Study 12391509 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (220 micro g/puff) at 2 puffs twice daily for 3 months
Number of subjects: 36
Study 12391509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9927363 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + CPAP (Continuous Positive Airway Pressure)
Number of subjects: 105
Study 9927363 — intervention group
Group type: COMPARATOR
Intervention: CT (Conservative Treatment)
Number of subjects: 105
Study 7484334 — intervention group
Group type: EXPERIMENTAL
Intervention: Confederate beverage choice and personal alcohol expectancy (social/physical pleasure)
Number of subjects: 133
Study 1962805 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured hypertension care
Number of subjects: 1169
Study 1962805 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured hypertension care)
Number of subjects: 1169
Study 6165189 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-MOP brand with high maximum concentration
Number of subjects: 7
Study 6165189 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-MOP brand with medium maximum concentration
Number of subjects: 7
Study 6165189 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-MOP brand with low maximum concentration
Number of subjects: 7
Study 6165189 — intervention group
Group type: EXPERIMENTAL
Intervention: All 8-MOP brands
Number of subjects: 7
Study 31021469 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mm abutment height group
Number of subjects: 33
Study 31021469 — intervention group
Group type: COMPARATOR
Intervention: 3 mm abutment height group
Number of subjects: 33
Study 28727632 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Totally Extraperitoneal (TEP)
Number of subjects: 0
Study 28727632 — intervention group
Group type: COMPARATOR
Intervention: Open Stoppa inguinal hernia repair
Number of subjects: 0
Study 26077218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative assessment (n=25)
Number of subjects: 78
Study 26077218 — intervention group
Group type: COMPARATOR
Intervention: End-of-course assessment (n=37)
Number of subjects: 78
Study 26077218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative assessment
Number of subjects: 78
Study 23506666 — intervention group
Group type: EXPERIMENTAL
Intervention: LACE DVD training for new HA users
Number of subjects: 29
Study 23506666 — intervention group
Group type: EXPERIMENTAL
Intervention: LACE DVD training for experienced HA users
Number of subjects: 29
Study 23506666 — intervention group
Group type: COMPARATOR
Intervention: Control group (new HA users with no training)
Number of subjects: 29
Study 21153417 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/day 3 hours before racing
Number of subjects: 27
Study 21153417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 19321312 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 1742
Study 19321312 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 1742
Study 19321312 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 1742
Study 19321312 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 1742
Study 19321312 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1742
Study 17367707 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA)‐rich diet (38% fat and 20% SFA)
Number of subjects: 97
Study 17367707 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO)‐rich diet (30% fat and 55% carbohydrate)
Number of subjects: 97
Study 17367707 — intervention group
Group type: COMPARATOR
Intervention: Monounsaturated fatty acid (MUFA)‐rich diet (38% fat and 22% MUFA)
Number of subjects: 97
Study 15286114 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11777296 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective α1-blockers
Number of subjects: 22
Study 11777296 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 22
Study 11777296 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or active treatment arms)
Number of subjects: 22
Study 9417523 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered, pooled platelet concentrates from random donors (F-PC)
Number of subjects: 530
Study 9417523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet B-irradiated, pooled platelet concentrates from random donors (UVB-PC)
Number of subjects: 530
Study 9417523 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered platelets obtained by apheresis from single random donors (F-AP)
Number of subjects: 530
Study 9417523 — intervention group
Group type: COMPARATOR
Intervention: Unmodified, pooled platelet concentrates from random donors (control)
Number of subjects: 530
Study 9417523 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (F-PC, UVB-PC, F-AP)
Number of subjects: 530
Study 7951680 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral physostigmine plus clonidine
Number of subjects: 10
Study 7951680 — intervention group
Group type: COMPARATOR
Intervention: Oral physostigmine alone
Number of subjects: 10
Study 7951680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3295935 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (500-700 micrograms/day)
Number of subjects: 4
Study 3295935 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of clonidine
Number of subjects: 4
Study 29249618 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery combined with relaxation therapy and other complementary therapies (e.g., hand and foot 'M' technique, education on pain management, relaxation exercises, respiration exercises, meditation, soothing music, nature sounds)
Number of subjects: 0
Study 29249618 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 0
Study 29249618 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 0
Study 29100709 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 3646
Study 29100709 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine (Cohort 2)
Number of subjects: 3646
Study 26745101 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood test (methylated BCAT1/IKZF1) offered to FIT non-participants
Number of subjects: 600
Study 26745101 — intervention group
Group type: COMPARATOR
Intervention: FIT (faecal immunochemical test)
Number of subjects: 600
Study 26745101 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood test offered to those who indicated FIT was inappropriate
Number of subjects: 600
Study 23621624 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer‐led, small‐group, structured writing using film clips from Women's Voices Women's Lives as a writing prompt
Number of subjects: 110
Study 21668963 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg/d
Number of subjects: 530
Study 21668963 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to duloxetine at Week 12)
Number of subjects: 530
Study 19502038 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand-guided nasotracheal intubation
Number of subjects: 60
Study 19502038 — intervention group
Group type: COMPARATOR
Intervention: Laryngoscopy-assisted nasotracheal intubation
Number of subjects: 60
Study 16862474 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intracutaneous suture
Number of subjects: 80
Study 16862474 — intervention group
Group type: COMPARATOR
Intervention: Donati stitches
Number of subjects: 80
Study 15298240 — intervention group
Group type: EXPERIMENTAL
Intervention: High group (maintained PP between 60 and 80 mmHg with phenylephrine)
Number of subjects: 12
Study 15298240 — intervention group
Group type: COMPARATOR
Intervention: Low group (no specific intervention mentioned)
Number of subjects: 12
Study 15298240 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 11532844 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia decision aid
Number of subjects: 205
Study 11532844 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study 14685376 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary puncture (P)
Number of subjects: 133